DDO-5936
规格
| Cas Number | 2355377-13-6 |
| 规格或纯度 | ≥95% |
| 纯度 | ≥95% |
| 包装 | 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 12.5 mg/mL (25.22 mM; ultrasonic and warming and heat to 60°C) |
| 过滤标签 | HSP,Cell Cycle/DNA Damage,Metabolic Enzyme/Protease |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | DDO-5936 是一种强效的特异性 Hsp90-Cdc37 PPI 抑制剂。DDO-5936 可用于结直肠癌的研究。 |
| 英文描述 |
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer In Vitro DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group . DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 0~80 mg/kg Administration: P.o. Result: Showed a moderate effect at the high dose group. Form:Solid IC50& Target:Hsp90-Cdc37 PPI |